论文部分内容阅读
心肌再灌注疗法的主要目标是使大多数患者尽快重建冠脉血流。鉴于血凝块溶解可能与溶栓药水平成正比,因而推测,治疗早期达到较高药浓度可能加速和增强再灌注。 219例急性心肌梗塞患者,于胸痛开始后148～185分钟静脉给予纤溶酶原激活剂。分为五种方案:A组(37例),30分钟内给予重组组织型纤溶酶原激活剂(rt-PA)1mg/kg(10%快速静注,其余滴注),继以0.25
The main goal of myocardial reperfusion therapy is to allow most patients to reestablish coronary flow as soon as possible. Given that blood clot lysis may be proportional to the level of thrombolytic agents, it is hypothesized that reaching a higher drug concentration early in treatment may accelerate and enhance reperfusion. 219 patients with acute myocardial infarction, 148 to 185 minutes after the start of chest pain intravenously plasminogen activator. The patients were divided into five groups: group A (37 cases), recombinant tissue plasminogen activator (rt-PA) 1 mg / kg (10% rapid intravenous injection and other instillation) within 30 minutes,